Review Article

GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

Romana Illig, Eckhard Klieser, Tobias Kiesslich, and Daniel Neureiter

1 Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Muellner HauptstraBe 48, 5020 Salzburg, Austria
2 Department of Internal Medicine I, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Muellner HauptstraBe 48, 5020 Salzburg, Austria

Correspondence should be addressed to Daniel Neureiter; d.neureiter@salk.at

Received 21 January 2013; Accepted 18 February 2013

Copyright © 2013 Romana Illig et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Due to unfavorable lifestyle habits (unhealthy diet and tobacco abuse) the incidence of gastroesophageal reflux disease (GERD) in western countries is increasing. The GERD-Barrett-Adenocarcinoma sequence currently lacks well-defined diagnostic, progressive, predictive, and prognostic biomarkers (i) providing an appropriate screening method identifying the presence of the disease, (ii) estimating the risk of evolving cancer, that is, the progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC), (iii) predicting the response to therapy, and (iv) indicating an overall survival—prognosis for EAC patients. Based on histomorphological findings, detailed screening and therapeutic guidelines have been elaborated, although epidemiological studies could not support the postulated increasing progression rates of GERD to BE and EAC. Additionally, proposed predictive and prognostic markers are rather heterogeneous by nature, lack substantial proofs, and currently do not allow stratification of GERD patients for progression, outcome, and therapeutic effectiveness in clinical practice. The aim of this paper is to discuss the current knowledge regarding the GERD-BE-EAC sequence mainly focusing on the disputable and ambiguous status of proposed biomarkers to identify promising and reliable markers in order to provide more detailed insights into pathophysiological mechanisms and thus to improve prognostic and predictive therapeutic approaches.

1. Introduction

In western countries, the particular importance of gastroesophageal reflux disease (GERD) as a main risk factor for Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC) promoted by obesity, hiatus hernia, and tobacco use has increased constantly [1, 2]. Chronic injury of the gastroesophageal junction by gastric acid or bile juice induces and promotes initially reversible metaplastic changes of the squamous epithelium which is confirmed by endoscopic examination and histomorphology [3–7]. The classical GERD-BE-EAC sequence postulates a stepwise progression over different stages of dysplasia [8, 9]. However, the postulated consecutive sequence during cancerogenesis of BE has not been proven up to now [10]. Reid et al. characterized this issue as “the paradox of Barrett’s esophagus,” pointing out that the majority of EACs (95%) arise without prior diagnosis of BE or GERD which possibly indicates that steps of the proposed linear BE-EAC development are skipped. Nevertheless, consequent surveillance of patients with GERD and concomitant BE within well-defined time intervals with biopsy of suspicious lesions may prevent dysplasia—caused by epithelial injuries due to GERD—from developing into invasive cancer.

Although no increase of EAC incidence was postulated in epidemiologic studies, about 5% of patients with GERD and 0.5% with BE developed EAC [2, 11–13].

As dysplasia and adenocarcinoma are diagnosed by pathologists routinely (based on Haematoxylin-Eosin-stained biopsies), the question arises how the “risk progression” of GERD to BE and further to dysplasia and EAC can be evaluated and predicted by prognostic molecular markers and ideally may predict therapeutic success. In this paper, we try to refer to these FAQs and to provide a panel of diagnostic and predictive markers.
2. Definition of GERD, BE, EAC, and Types of Requested Prognostic and Predictive Markers

(i) GERD describes the chronic reflux of gastric acid or bile fluid to the esophagus resulting in metaplastic changes of the normal squamous esophageal tissue to columnar epithelium (BE) (for review, see [5]). The metaplastic changes—assessed by upper endoscopy and histological approval—comprise proximal columnar epithelia with intestinal type goblet cells, the junctional (cardial) subtype with mucous secreting glands and the gastric fundus subtype with parietal and chief cells [7, 14]. Up to now, a uniform definition of Barrett’s esophagus (BE) remains controversial (e.g., which type of metaplastic changes qualifies the diagnosis BE?) leading to the striking statement “no goblets, no Barrett’s” [4, 5], disregarding that nongoblet elements may also be involved in the malignant transformation of BE assessed by Sucrease-Isomaltase and dipeptidyl peptidase IV protein expression [15]. Whereas the detection of intestinal goblet cells in BE samples is already established by using histochemical staining like Alcian-PAS, the diagnosis of dysplasia in BE remains a great challenge due to inter- and intraobserver variation in histology grading (discussed later); therefore, the incidence of dysplasia inside BE varies from 5, to 10% according to national screening efforts and surveillance programs [16]. While diagnostic criteria of BE with dysplasia are relatively well defined by combining cytological and architectural changes, their prospective validation is still missing (for details, see [17–21]). Moreover, diagnosis of the progression from BE with dysplasia to invasive EAC becomes sometimes impracticable when biopsies are small and criteria of invasiveness are mimicked by distorted rearrangement of glandular structures caused by ulceration and inflammation. At present, using the grade of dysplasia in BE represents the best biomarker in predicting the progression probability for nondysplastic BE (about 0.5%), low-grade dysplasia in BE (13%), and up to 40% in high-grade dysplasia in BE [22, 23]. Therefore, screening surveillance of BE and dysplasia remains still important to detect precursor lesions of EAC in order to avert the disastrous fate of progressive EAC which is characterized by an overall 5-year survival rate between 3.7% and 15.6% [24].

(ii) Complexity factor “diagnosis”: Several issues in BE as well as in EAC detection are still unsolved. The majority of patients with BE remain undiagnosed [25–28], and/or patients with BE and dysplasia are often mis- or over-diagnosed due to inter- and intra-observer errors [10, 29, 30]. Based on the low progression rate of BE to EAC [11], endoscopic and biotic surveillance studies could not convey a significant benefit for controlled patients [31]. Therefore, the demand for reliable biomarkers regarding prognosis and prediction of patients with BE without/dysplasia as well as with EAC still remains indispensable.

(iii) Definition of predictive and prognostic factors (for reviews, see [32–34]): The widely used term “biomarker” represents a marker for physiological or pathological processes or therapeutic response. The clinical characteristics or endpoints (like patient performance status or disease-free period) which should be achieved by these biomarkers as well as methods applied (e.g., genome, transcriptome, proteome, or metabolome) are rather heterogeneous. The term “predictive factor” refers to the use as biomarker for prediction of the statistical probability of disease recurrence, metastasis, or tumor-related death as well as for prediction of specific therapeutic effectiveness.

As recommend by Pepe et al. [35] and McShane et al. [36], different and clearly defined “milestones” must be passed during biomarker development to evaluate their clinical prognostic and predictive potentials: starting with data obtained from experimental cell culture up to retrospective and prospective validation studies resulting in clinical applicability and significant decreasing mortality, and completed by increasing health and cost benefits.

3. “Classical” Genetic and Molecular Alterations in GERD, BE, and EAC

During carcinogenesis of BE to EAC, heterogeneous hallmarks of molecular changes are described in the literature [8, 37, 38].

(a) Genetic abnormalities of BE include loss of genetic information (especially loss of 9p21, 5q, 13q, 17p, and 18q), whereas for progressive disease, a more extensive imbalance including gain of genetic information (especially gain of 2p, 8q, and 20q) is observed. Finally, enhanced chromosomal instability could be found in the progressive lesions of EAC. (b) These genetic abnormalities cause consecutive deregulations of their products like tumor suppressor genes (p53 (loss of 17p), p16 (loss of 9p21), fragile histidine triad protein (FHIT), adenomatous polyposis coli (APC) (loss of 5q), retinoblastoma (Rb) (loss of 13q)), cell cycle regulatory factors (cyclin D1 and MD2 mouse double minute 2 homolog), growth factor receptors (EGFR (epidermal growth factor receptor), TGF-α (transforming growth factor)), c-erB2 and cell adhesion molecules (E- and P-Cadherin and α- and β-Catenin), as well as proteases (uPA, urokinase-type plasminogen activator) according to the hallmarks of cancer [39]. Additionally, molecular alterations are associated with epigenetic changes such as the methylation and acetylation status as known for APC [40] and p16 [41].

(c) Distinct changes in expression pattern of various miRNAs (microRNA) have been demonstrated in BE or EAC. miRNAs are small regulatory noncoding RNA molecules (18–22mer) which inhibit the expression of their target genes on posttranscriptional levels; about 30% of human genes are estimated to be regulated by miRNAs [42]. Using global miRNA expression profiling or in situ hybridization, several miRNAs (miR-143, -199a, 3p, -199a, 5p, -100, -99a [43], miR-16-2, -30E, and -200a [44]) have been identified whose expression was associated with reduced overall survival in EAC [43, 44]. A more detailed insight into the relevance of different miRNA expression has been provided recently by Leidner et al. [45] in n = 20 EAC samples; next generation sequencing and qRT-PCR identified a total of 26 miRNA that are deregulated in EAC more than
4. Predictive and Prognostic Factors for GERD, BE, and EAC?

Previous reviews in this area and proclaimed further investigations thereof in gastroenterological oncology (for review, see Ong et al. [111], Fang et al. [112], and Huang and Hardie [113]). Usually, biomarkers are classified as markers for risk evaluation in patients with GERD to develop EAC or as biomarkers for predictive and prognostic evaluation in patients with diagnosed EAC. Hence, the presented data implicate—and pretend—that we have already reached “the end of the road” with available and significant biomarkers. However, detailed assessment and comparison with other cancers, such as breast, prostate, as well as colorectal [114], reveal them in a rather disillusioning light. Since endoscopicoptic surveillance studies yielded no significant benefit for BE patients [31], and prognosis of patients with EAC still is disastrous [24], further intensive experimental and clinical research of (molecular) pathological mechanisms are required urgently.

Based on studies regarding potential predictive and prognostic markers within the GERD-BE-EAC sequence, we classified them into four groups (Table I and Figure 1) and illustrated a patient-specific disease sequence (Figure 2; for details, see reviews [111–113, 115]): (A) diagnostic biomarkers—indicate the presence of disease, (B) progression biomarkers—indicate the risk of developing cancer, that is, progression from BE to EAC, (C) predictive biomarkers—predict response to therapy, and (D) prognostic biomarkers—indicate overall survival, that is, prognosis for EAC.

4.1. A = Diagnostic Biomarkers—Indicate the Presence of Disease. The conventional approach for detection and diagnosis is the histochemical analysis of endoscopically derived biopsies of the gastro-esophageal junction, albeit the proposed importance of histological subtypes, the gastric fundus, the cardiac subtype, and the metaplastic columnar epithelium with intestinal-type goblet cells remains unclear [116]. The relevance of these factors has been discussed for years, but prospective studies clarifying the prognostic ability of these histological subtypes are currently not available. Additionally, the trefoil factor 3 (TFF3) combined with a noninvasive diagnostic technique has been investigated intensively in otherwise asymptomatic BE patients [48, 49]. Their results are promising, possibly enabling a selective screening of patients; however, these findings require independent validation and assessment before further clinical application.

4.2. B = Progression Biomarkers—Indicate the Risk of Progression from BE to EAC. Similar to the situation for diagnostic biomarkers (A), the most frequently applied progression marker for clinicians and pathologists is the degree of dysplasia in obtained biopsies. Although the inter- and intra-observer error [10, 29, 30] is extremely unsatisfying, studies confirmed that high-grade dysplasia is associated with a 40% higher risk for progression of BE to EAC [22, 23]. Therefore, a primary goal should be the standardization of criteria for dysplasia based on conventional Haematoxylin-Eosinstained specimens in order to avoid under- and overdiagnosis [10, 29, 30]. Several molecular markers are evaluated too (see Table I)—the most promising ones according to their statistical robustness (based on OR and RR) are MCM2 expression pattern (highest OR of about 136, whereby the confidence interval is large, reducing the potency of this marker). Loss of heterozygosity on distinct gene loci, especially at 17p, indicates a high progression probability from BE to EAC. The expression pattern of P53 as well as the hypermethylation of p16 and APC suggests high potency, followed by the cell-cycle-associated proteins Cyclin A and D1. These markers were intensively evaluated within retrospective studies but did not succeed the direct transfer to clinical practice, especially due to cost- and time-intensive experimental work. In our experience, the immunohistochemical evaluation of P16 and P53 is well established in pathological diagnostics, whereby the quantification and standardization remains still an unsolved problem.

4.3. C = Predictive Biomarkers—Predict Response to Therapy. As displayed in Table I, the number of potential predictive biomarkers is considerably lower than all other categories accompanied by mainly nonsignificant P values. Additionally, biomarkers of category A such as p53 and p16 are also listed in category C, indicating the overall impact of these biomarkers. In sum, the limited number of available and reliable C-markers must be considered as a starting point for inevitable research in the establishment of reliable predictive biomarkers.

4.4. D = Prognostic Biomarkers—Indicate Overall Survival—Prognostic in EAC. It is not surprising that the majority of
**Figure 1:** GERD-associated progression for Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC). A–D refer to biomarkers which could be most relevant at the indicated stages of the disease progression (according to Table 1). Therefore A, B, C, and D stand for diagnostic, progressive, predictive, and prognostic biomarkers, respectively.

**Figure 2:** Proposed approach for identification of novel biomarkers for the GERD-BE-AEC sequence. Based on the heterogeneous and patient-specific progression sequence from BE to EAC, the figure indicates the disease stages and mandatory (histology, IHC) and supplementary potential methods for investigation of putative biomarkers for progression, prediction, and prognosis. These data possibly result in an evidence-based stratification of patients for various available therapies (X–Z) based on a rational selection and evaluation of specific biomarkers. Abbreviations. Esophageal adenocarcinoma: AEC; dysplasia: Dys; fluorescence in-situ hybridization: FISH; gastro-esophageal reflux disease: GERD; immunohistochemistry: IHC.

Biomarkers are listed in the last category—displaying the typical survey of hallmarks of cancer [39] reaching from self-sufficiency in growth signals (Cyclin D1, EGFR, Ki-67, Her2/neu, TGF-α), insensitivity to growth inhibitory signals (TGF-β1, APC, P21), evasion of programmed cell death (Bcl-2, COX-2, NF-κB), limitless replicative potential (Telomerase), sustained angiogenesis (CD105, VEGF), invasion and metastasis (Cadherin, uPA, TIMP), tumor differentiation
TABLE 1: Summary of investigated and published biomarkers in the GERD-BE-EAC axis. The categorization is based on four groups according to their potential usage as A = Diagnostic Biomarker indicates the presence of disease, B = Progression Biomarker indicates the risk of developing cancer—progression in BE to EAC, C = Predictive Biomarker predicts response to therapy (CTX, RTX, photodynamic therapy), or D = Prognostic Biomarker indicates overall survival—prognostic in EAC (survival, recurrence).

| Biomarker | Method | Remarks/findings | OR/RR/P value | Refs |
|-----------|--------|------------------|---------------|------|
| **A = Diagnostic Biomarker** | | | | |
| TFF3 | IHC, esophageal cytosponge samples for BE combined with IHC for TFF3 | novel nonendoscopic screening modality in a prospective cohort study | | |
| | | biomarker to screen asymptomatic patients for BE; TFF3 protein was expressed at the luminal surface of BE (not at normal esophageal or gastric mucosa) | | |
| Chromosomes 7 and 17 (copy number changes) | ICDA & FISH | chromosomal gains in early stages of BE; valuable adjunct to conventional cytology to detect dysplasia or EAC | IND/LGD: 75% sensitivity, (76% specificity) HGD/EAC: 85% sensitivity, (84% specificity) | [50] |
| 8q24 (C-MYC), 17q12 (HER2), and 20q13 (copy number changes) | FISH | chromosomal gains in early stages of BE; represents a valuable adjunct to conventional cytology to detect dysplasia or EAC | LGD (50% sensitivity) HGD (82% sensitivity) EAC (100% sensitivity) | [51] |
| 17q11.2 (ERBB2) | Southern blotting, microarray analysis | amplified copies of the ERBB2 gene in EAC | 10-fold amplification in 3 of 25 (12%) tumors identified 10 of 11 normal’s; and 42 of 43 EAC’s correctly | [52] |
| Serum proteomic pattern analysis | mass spectrometry | several limitations due to applied technology | | [53] |
| **B = Progression Biomarkers** | | | | |
| P53 positivity | IHC | limited efficacy as a single progression biomarker | OR 11.7 (95% CI: 1.93–71.4) | [54] |
| P53 positivity | IHC | positive in 4/31 that regressed, 3/12 that persisted, and 3/5 that progressed to HGD or EAC | RR not available | [55] |
| DNA content abnormalities | flow cytometry | higher relative risk for EAC in patients with tetraploidy (4N) or aneuploidy (>6%) | tetraploidy: RR 7.5 (95% CI: 4–14) (P < 0.001) aneuploidy: RR 5.0 (95% CI: 2.7–9.4) (P < 0.001) | [56] |
| DNA content abnormalities | flow cytometry | 4N fraction cut point of 6% for cancer risk aneuploid DNA contents of 2.7N were predictive of higher cancer risk presence of both 4N fraction of 6% and aneuploid DNA content of 2.7N is highly predictive for progression | RR 11.7 (95% CI: 6.2–22) RR 9.5 (95% CI: 4.9–18) RR 23 (95% CI: 10–50) | [57] |
| LOH of 15q and 9p and DNA content abnormalities | flow cytometry, PCR | 17p(p53) LOH associated with higher risk of progression to HGD + EAC | HGD: RR 3.6 (P = 0.02) EAC: RR 16 (P < 0.001) | [58] |
| | flow cytometry, PCR | combined LOH of 17p and 9p and DNA content abnormalities can best predict progression to EAC LOH of 17p alone LOH of 9p alone Aneuploidy alone Tetraploidy alone | RR 38.7 (95% CI: 10.8–138.5) not clinical applicable RR 10.6 (95% CI: 5.2–21.3) RR 2.6 (95% CI: 1.1–6.0) RR 8.5 (95% CI: 4.3–17.0) RR 8.8 (95% CI: 4.3–17.7) | [59] |
| Biomarker                                      | Method                      | Remarks/findings                                                                 | OR/RR/P value | Refs  |
|-----------------------------------------------|-----------------------------|----------------------------------------------------------------------------------|---------------|-------|
| mutations of p16 and p53 loci (clonal diversity measurements) | flow cytometry, PCR         | significant predictors for EAC progression, not clinical applicable               | \( P = 0.001 \) | [60]  |
| EGFR                                          | IHC                         | overexpression in HGD/EAC correlation between degree of dysplasia and level of ectopic luminal surface MCM2 expression | 35% of HGD/80% of EAC specimens MCM2-positive staining in 42% (19/45) of BE samples | [61]  |
| MCM2                                          | IHC                         | surface expression of cyclin A in BE samples correlates with the degree of dysplasia | OR 7.5 (95% CI: 1.8–30.7) \(( P = 0.016 \) | [62]  |
| Cyclin A                                      | IHC                         | association with increased risk of EAC                                             | OR 6.85 (95% CI: 1.57–29.91) | [63]  |
| Cyclin D1                                      | IHC                         | association with increased risk of progression to HGD/EAC                         | OR 1.74 (95% CI: 1.33–2.2) | [64]  |
| hypermethylation of p16 (CDK12A)              | RT-PCR                      | association with increased risk of progression to HGD/EAC                         | OR 1.80 (95% CI: 1.08–2.81) | [41]  |
| hypermethylation of RUNX3                     | RT-PCR                      | association with increased risk of progression to HGD/EAC                         | OR 1.77 (95% CI: 1.06–2.81) | [41]  |
| hypermethylation of HPP1                      | PCR                         | predictor of progression to HGD/EAC                                              | OR 14.97 (95% CI: 1.73–inf.) | [65]  |
| hypermethylation of p16 and APC               | RT-PCR                      | age dependent; predicts 60.7% of progression to HGD/EAC within 2 yrs              | RR not available (90% specificity) | [66]  |
| gene methylation panel                        | microarray analysis         | 64 genes up regulated 110 genes down regulated in EAC                            | \( P = 0.05 \) | [67]  |
| Cathepsin D, AKRIB10, and AKRIC2 mRNA levels  | Western blotting, qRT-PCR   | dysregulation predicts progression to HGD/EAC                                    | AKR2C2: ↑ levels in BE \(( P < 0.05 \) but ↓ levels in EA \(( P < 0.05 \) 60% with LGD; 73% with HGD, and 100% with EAC (total number of samples = 56) | [68]  |
| DNA abnormalities                              | ICDA                        | aneuploidy predicts progression to EAC                                            | \( P < 0.001 \) | [69]  |
| ACIS                                          | DCM                         | frequency and severity of aneuploidy predicts progression to EAC relationship between DICM status and progression to HGD/EAC | \( P < 0.0001 \) | [70]  |
| SNP-based genotyping in BE/EAC specimens      | flow cytometry, 33K SNP array | copy gains, losses, and LOH increased in frequency and size between early and late stage of disease | \( P < 0.001 \ (BE) \) | [72]  |

C = Predictive Biomarkers

- p16 allelic loss: FISH decreased response to photodynamic therapy OR 0.32 (95% CI: 0.10–0.96) [73]
- DNA ploidy abnormalities: ICDA DNA ploidy as a covariate value for recurrence HR 6.3 (1.7–23.4) \(( P < 0.0015 \) [74]
- HSP27: IHC association between low HSP27 expression and no response to neoadjuvante chemotherapy \( P = 0.049 \) and \( P = 0.032 \) [75]
- Ephrin B3 receptor: microarray response prediction in EAC in patients with Ephrin B3 receptor positive versus Ephrin B3 receptor negative Response rate <50%: 3 (15.8) versus 16 (84.2) \(( P < 0.001 \) comprehensive panel of genetic polymorphisms on clinical outcomes in 210 esophageal cancer patients [76]
- Genetic polymorphisms: qRT-PCR association between individual single nucleotide polymorphisms and clinical outcomes [77]
| Biomarker | Method | Remarks/findings | OR/RR/P value  |
|-----------|--------|------------------|---------------|
| P21       | IHC    | alteration in expression correlated with better CTX-response | $P = 0.011$  |
| P53       | IHC    | alteration in expression correlated with better CTX-response | $P = 0.011$  |
| ERCC1     | IHC    | ERCC1-positivity predicts CTX-resistance and poor outcome | $P < 0.001$  |
| DCK       | RT-PCR, IHC | prognostic 4-gene signature in EAC predicts 5-year survival | 0/4 genes dysregulated: 58% (95% CI: 36%–80%), 1-2/4 genes dysregulated: 26% (95% CI: 20%–32%), 3-4/4 genes dysregulated: 14% (95% CI: 4%–24%) ($P = 0.001$)  |
| PAPSS2    | RT-PCR, IHC |  |
| SIRT2     | IHC |  |
| TRIM44    | IHC |  |
| p16 loss  | FISH | association between therapy response status and FISH positivity | $P = 0.04$  |
| C-MYC gain| FISH | low expression correlates with lymph node metastasis | $P = 0.048$  |
| ASS expression | microarrays |  |
| miRNA expression profiles | microarray, qRT-PCR | association with prognosis (e.g. low levels of mir-375 in EAC → worse prognosis) HR = 0.31 (95% CI: 0.15–0.67) ($P < 0.005$)  |
| Genomic alterations | MLPA | reverse association between survival and DNA copy number alterations (>12 aberrations → low mean survival) | $P = 0.003$  |
| Cyclin D1 | FISH, IHC | 2 of 3 genotypes confers to ↓ survival | $P = 0.0003$  |
| EGFR      | IHC    | ↓ expression = ↓ survival | $P = 0.07$  |
| Ki-67     | IHC    | ↓ expression = ↓ survival | $P = 0.034$  |
| Her2/neu  | FISH   | amplification = ↓ survival | $P = 0.03$  |
| TGF-α     | IHC, ISH | high levels = tumor progression and lymph node metastasis | $P = 0.025$ and $P < 0.05$  |
| TGF-β1    | qRT-PCR | overexpression = ↓ survival | $P = 0.0255$  |
| APC       | RT-PCR | high plasma levels = ↓ survival | $P = 0.0317$  |
| Bcl-2     | IHC    | expression = ↓ survival | $P = 0.03$  |
|          | IHC, RT-PCR | ↑ expression = ↓ survival, ↑ TN-stage, and recurrence RR of death: 3.4 (CI: 1.3–8.9) ($P < 0.02$) |
| COX-2     | IHC    | strong staining = ↓ survival | $P = 0.03$  |
|          | IHC    | strong staining = ↓ survival, distant metastasis, and recurrence | $P = 0.002, P = 0.02$, and $P = 0.05$  |
| NF-κB     | IHC    | activated NF-κB = ↓ survival, and ↓ disease free survival | $P = 0.015$ and $P = 0.010$  |
| Telomerase | Southern blot analysis, RT-PCR | higher telomere-length ratio = ↓ survival |  |
Table 1: Continued.

| Biomarker                  | Method         | Remarks/findings                                      | OR/RR/P value | Refs |
|----------------------------|----------------|-------------------------------------------------------|---------------|------|
| CD105                      | IHC            | expression = ↓ survival, angiolymphatic invasion      | P < 0.01      |      |
|                            |                | lymph node metastasis, T-stage                        | P < 0.01      | [103]|
|                            |                | distant metastasis, survival, expression = survival   | P < 0.01      |      |
| VEGF                       | IHC            | lymph node metastasis, T-stage                        | P < 0.01      | [103]|
|                            |                | distant metastasis, survival                          | P < 0.01      |      |
| Cadherin IHC               | IHC            | level = survival, expression = survival               | P = 0.05      | [89] |
| uPA ELISA                  |                | uPA = survival                                        | P = 0.0002    | [104]|
| TIMP                       | IHC, RT-PCR    | expression = survival, disease stage                  | P = 0.007 and | [105]|
| Promoter hypermethylation  | IHC, methylation specific PCR | if >50% of gene profile methylated = survival, and earlier recurrence | P = 0.05 and | [106]|
| of multiple genes          |                |                                                       | P = 0.046     |      |
| MGMT hypermethylation      | IHC, methylation specific PCR | correlation with higher tumor differentiation | P = 0.0079    | [107]|

ACIS: automated cellular imaging system; ASS: argininosuccinate synthase; APC: adenomatous polyposis coli; BE: Barrett’s esophagus; COX: cyclooxygenase; DCK: deoxycytidine kinase; DICM: digital image cytometry; EAC: esophageal adenocarcinoma; EGFR: epidermal growth factor receptor; ELISA: enzyme-linked immunosorbent assay; FISH: fluorescence in-situ-hybridization; ICDA: image cytometric DNA analysis; HSP27: Heat-shock protein 27; IHC: immunohistochemistry; LOH: loss of heterozygosity; PAPSS2: 3-phosphoadenosine 5-phosphosulfate synthase 2; PCR: polymerase chain reaction; qRT: quantitative reverse transcriptase; MLPA: multiplex ligation dependent probe amplification; NF-κB: nuclear factor kappa B; SIRT2: Sirtuin 2; SNP: single nucleotide polymorphism; TFF3: Trefoil factor 3; TGF: transforming growth factor; TIMP: tissue inhibitors of metalloproteinases; TRIM44: Tripartite motif-containing 44; uPA: urokinase-type plasminogen activator; VEGF: vascular endothelial growth factor.

Table 2: Synopsis of biomarkers in the GERD-BE-EAC axis. According to Table 1, most promising biomarkers are summarized indicating that only dysplasia is involved in all four categories. Dysplasia can be used as diagnostic biomarker as well as to assess the risk of progression to EAC or response to therapy and is associated with poor survival (↓ survival).

|                  | Dysplasia | P53 | P16 | P21 | Growth factors | Cell cycle |
|------------------|-----------|-----|-----|-----|----------------|------------|
| A = Diagnostic Biomarker | ✓         | ✓   | ✓   | ✓   | ✓              |            |
| B = Progression Biomarker | ✓         | ✓   | ✓   | ✓   | ✓              |            |
| C = Predictive Biomarker | ✓         | ✓   | ✓   | ✓   |                |            |
| D = Prognostic Biomarker | ✓         | ✓   | ✓   | ✓   | ↓ survival     | ↓ survival |
Finally, two major questions arise and are still unsolved: (i) why are proposed biomarkers not (yet) really embedded in clinical routine, and (ii) what impairs the identification of more reliable and significant biomarkers?

First of all, two major limitations are the technical and financial aspects. Special molecular biological techniques require fresh frozen samples; DNA-, RNA-extraction, and nucleic acid amplification as well as subsequent hybridization or sequencing are time-consuming and need special facilities which are, again, cost intensive. Additionally, validation of specific methods to detect genetic and epigenetic alterations is still not completed. In conclusion, costs and practicability of these biomarkers are the limiting factors until now [111].

Possible answers to the second question are that more relevant entities like inflammation or epithelial-mesenchymal transition (EMT), which have not yet been completely considered, should be integrated in the evaluation-process of biomarkers for GERD, BE and EAC.

The potential role of the localized inflammation in disease prediction and prognosis is currently rather underestimated in experimental and clinical investigations. Generally, it has been shown that inflammation influences cancerogenesis by key mediators including reactive oxygen species (ROS), NF-κB, inflammatory cytokines, prostaglandins, and specific microRNAs (miRNAs) [119]. Poehlmann et al. comprehensively reviewed the role of inflammation on genetic and epigenetic changes in BE and EAC focusing on oxidative stress and the NF-κB-pathway [120]. Beside NF-κB and COX-2 (see Table 1), other transmitters of inflammation like chemokines or cytokines should be investigated as possible biomarkers.

Additionally, the process of EMT with its key players Snail, Twist, and ZEB and their repressed target protein E-Cadherin is essentially linked to development, regeneration, inflammation, and cancerogenesis [121]. Several ontogenic pathways (e.g., WNT-, Hedgehog-, or Notch-signaling) are involved in EMT regulation and have also been associated with pathogenesis of BE to EAC as reviewed by Chen et al. [38]. Furthermore, increased expression of SLUG is associated with progression of EAC by consecutive repression of E-Cadherin indicating a role of EMT in EAC. Therefore, subsequent clinical trials have to be set up to elucidate distinct mechanisms of EMT in the pathogenesis of or as specific biomarkers in BE or EAC [122].

5. Approach and Outlook

The probability to find one single specific biomarker providing all diagnostic, predictive, and prognostic significance in GERD, BE, and/or EAC is rather utopian, and a panel of biomarkers maybe will solve this problem [81, 123, 124]. Upcoming new technologies such as RNA and DNA microarrays, epigenetics, and proteomics in association with bioinformatics give hope to find novel and reliable biomarkers in gastrointestinal tumors and especially for prognosis and prediction of BE and EAC [114]. These technologies may provide insights in this rather complex sequence of GERD-BE-EAC; for instance, Kaz et al. [125] stratified BE and EAC by methylation signatures and molecular subclasses using DNA methylation profiling. Interestingly, the authors found an increase of methylation during disease progression—supporting the postulated GERD-BE-EAC sequence and promoting studies of biomarkers based on epigenetic mechanisms which are specific for particular steps in the pathogenetic sequence. Additionally, miRNA profiling by Ko et al. [126] discovered five miRNAs which are significantly expressed in patients with EAC with and without complete remission after therapeutic interventions, whereby the connection of these interesting data to other prognostic/predictive biomarkers in EAC has not been performed. As mentioned by Jankowski and Odze [114], the new technologies are associated with specific limitations; RNA and DNA array techniques are retrospective and are frequently lacking phenotype controls. Epigenetic experimental approaches often showed an overlap of methylation pattern between normal and precancerous tissues with no possibility of discrimination between them. Proteomics is time-consuming and not applicable for daily routine work. This seems also true for bioinformatics' techniques.

As depicted in Figure 2, every stage of disease demands intensive morphological, genetic, as well as epigenetic analysis and consequently an exorbitant research effort due to the heterogeneity within the GERD-BE-EAC sequence. However, only consistent generating of data from patients with GERD, GERD with BE, GERD with EAC, or GERD with BE and EAC will allow integrative analysis and research, even if this implies that patients with GERD will be under consecutive, perhaps lifelong surveillance. Therefore, consolidation and evaluation of our intensive but partial not coherent findings regarding the "puzzle" of GERD-BE-EAC represent the first steps to discover the best biomarkers for diagnosis, therapy, and prognosis.

Abbreviations

| Abbreviation | Description                          |
|--------------|--------------------------------------|
| ACIS         | Automated cellular imaging system    |
| ASS          | Argininosuccinate synthase            |
| APC          | Adenomatous polyposis coli           |
| BE           | Barret's esophagus                    |
| COX          | Cyclooxygenase                        |
| DCK          | Deoxycytidine kinase                  |
| DICM         | Digital image cytometry               |
| EAC          | Esophageal adenocarcinoma             |
| EGFR         | Epidermal growth factor receptor      |
| ELISA        | Enzyme linked immunosorbent assay     |
| EMT          | Epithelial-mesenchymal-transition     |
| FHTT         | Fragile histidine triad protein       |
| FISH         | Fluorescence in-situ-hybridization    |
| GERD         | Gastro-esophageal reflux disease      |
| ICDA         | Image cytometric DNA analysis         |
| HSP27        | Heat-shock protein 27                 |
| IHC          | Immunohistochemistry                  |
| LOH          | Loss of heterozygosity                |
| PAPSS2       | 3′′-phosphoadenosine 5′′-phosphosulfate synthase 2 |
PCR:  Polymerase chain reaction
qRT:  Quantitative reverse transcriptase
MDM2:  Mouse double minute 2 homolog
MLPA:  Multiplex ligation dependent probe amplification
NF-κB:  Nuclear factor kappa B
Rb:  Retinoblastoma
SIRT2:  Sirtuin 2
SNP:  Single nucleotide polymorphism
TFF3:  Trefoil factor 3
TGF:  Transforming growth factor
TIMP:  Tissue inhibitors of metalloproteinases
TRIM44:  Tripartite motif-containing 44
uPA:  Urokinase-type plasminogen activator
VEGF:  Vascular endothelial growth factor.

Acknowledgments
The authors thank Professor Dr. Otto Dietze for his crucial suggestions regarding paper preparation. They apologize to colleagues whose work could only be cited indirectly. This work was supported by the Wissenschaftlicher Verein der Pathologie Salzburg/Austria.

References
[1] O. T. Nebel, M. F. Fornes, and D. O. Castell, “Symptomatic gastroesophageal reflux: incidence and precipitating factors,” American Journal of Digestive Diseases, vol. 21, no. 11, pp. 953–956, 1976.
[2] J. H. Rubenstein, H. Morgenstern, H. Appelman et al., “Prediction of Barrett’s esophagus among men,” American Journal of Gastroenterology, 2013.
[3] B. J. Reid, “Barrett’s esophagus and esophageal adenocarcinoma,” Gastroenterology Clinics of North America, vol. 20, no. 4, pp. 817–834, 1991.
[4] W. M. Weinstein and A. F. Ippoliti, “The diagnosis of Barrett’s esophagus: goblets, goblets, goblets,” Gastrointestinal Endoscopy, vol. 44, no. 1, pp. 91–95, 1996.
[5] C. L. Booth and K. S. Thompson, “Barrett’s esophagus: a review of diagnostic criteria, clinical surveillance practices and new developments,” Journal of Gastrointestinal Oncology, vol. 3, no. 3, pp. 232–242, 2012.
[6] R. F. Souza, K. Krishnan, and S. J. Spechler, “Acid, Bile, and CDX: the ABCs of making Barrett’s metaplasia,” American Journal of Physiology, vol. 295, no. 2, pp. G211–G218, 2008.
[7] R. J. Playford, “New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus,” Gut, vol. 55, no. 4, pp. 442–443, 2006.
[8] G. J. S. Jenkins, S. H. Doak, J. M. Parry, F. R. D’Souza, A. P. Griffiths, and J. N. Baxter, “Genetic pathways involved in the progression of Barrett’s metaplasia to adenocarcinoma,” British Journal of Surgery, vol. 89, no. 7, pp. 824–837, 2002.
[9] B. B. Koppert, B. P. L. Wijnhoven, H. Van Dekken, H. W. Tilanus, and W. N. M. Dinjens, “The molecular biology of esophageal adenocarcinoma,” Journal of Surgical Oncology, vol. 92, no. 3, pp. 169–190, 2005.
[10] B. J. Reid, X. Li, P. C. Galipeau, and T. L. Vaughan, “Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis,” Nature Reviews Cancer, vol. 10, no. 2, pp. 87–101, 2010.
[11] N. J. Shaheen, M. A. Crosby, E. M. Bozymski, and R. S. Sandler, “Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?” Gastroenterology, vol. 119, no. 2, pp. 333–338, 2000.
[12] M. Sikkema, P. J. F. de Jonge, E. W. Steyerberg, and E. J. Kuipers, “Risks of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis,” Clinical Gastroenterology and Hepatology, vol. 8, no. 3, pp. 235–244, 2010.
[13] R. C. Haggitt, “Barrett’s esophagus, dysplasia, and adenocarcinoma,” Human Pathology, vol. 25, no. 10, pp. 982–993, 1994.
[14] S. J. Spechler, P. Sharma, R. F. Souza, J. M. Inadomi, and N. J. Shaheen, “American gastroenterological association technical review on the management of Barrett’s esophagus,” Gastroenterology, vol. 140, no. 3, pp. e18–e52, 2011.
[15] P. Chaves, P. Cardoso, J. C. Mendes De Almeida, A. D. Pereira, C. N. Leitão, and J. Soares, “Non-goblet cell population of Barrett’s esophagus: an immunohistochemical demonstration of intestinal differentiation,” Human Pathology, vol. 30, no. 11, pp. 1291–1295, 1999.
[16] S. J. Spechler, “Barrett’s esophagus,” Seminars in Oncology, vol. 21, no. 4, pp. 431–437, 1994.
[17] R. H. Riddell, H. Goldman, and D. F. Ransohoff, “Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications,” Human Pathology, vol. 14, no. 11, pp. 931–966, 1983.
[18] J. R. Goldblum, “Barrett’s esophagus and Barrett’s-related dysplasia,” Modern Pathology, vol. 16, no. 4, pp. 316–324, 2003.
[19] H. Barr, M. P. Upton, R. C. Orlando et al., “Barrett’s esophagus: histology and immunohistology,” Annals of the New York Academy of Sciences, vol. 1232, pp. 76–92, 2011.
[20] G. B. Baretton and D. E. Aust, “Barrett’s esophagus. An update,” Pathologie, vol. 33, no. 1, pp. 5–16, 2012.
[21] J. F. Fléjou and M. Svrcck, “Barrett’s oesophagus—a pathologist’s view,” Histopathology, vol. 50, no. 1, pp. 3–14, 2007.
[22] W. L. Curvers, F. J. Ten Kate, K. K. Krishnadath et al., “Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated,” American Journal of Gastroenterology, vol. 105, no. 7, pp. 1523–1530, 2010.
[23] S. Wani, S. R. Puli, N. J. Shaheen et al., “Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: a meta-analysis and systematic review,” American Journal of Gastroenterology, vol. 104, no. 2, pp. 502–513, 2009.
[24] V. H. Coupland, W. Allum, J. M. Blazey et al., “Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study,” BMC Cancer, vol. 12, article 11, 2012.
[25] B. Schlansky, A. J. Dimarino Jr., D. Loren et al., “A survey of oesophageal cancer: pathology, stage and clinical presentation,” Alimentary Pharmacology & Therapeutics, vol. 23, no. 5, pp. 587–593, 2006.
[26] L. B. Gerson, K. Shetler, and G. Triadaﬁlopoulos, “Prevalence of Barrett’s esophagus in asymptomatic individuals,” Gastroenterology, vol. 123, no. 2, pp. 461–467, 2002.
[27] D. K. Rex, O. W. Cummings, M. Shaw et al., “Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn,” Gastroenterology, vol. 125, no. 6, pp. 1670–1677, 2003.
[28] E. M. Ward, H. C. Wolfisen, S. R. Achem et al., “Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms,” American Journal of Gastroenterology, vol. 101, no. 1, pp. 12–17, 2006.
[29] B. J. Reid, R. C. Haggitt, C. E. Rubin et al., "Observer variation in the diagnosis of dysplasia in Barrett's esophagus," *Human Pathology*, vol. 19, no. 2, pp. 166–178, 1988.

[30] E. Montgomery, M. P. Bronner, J. R. Goldblum et al., "Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation," *Human Pathology*, vol. 32, no. 4, pp. 368–378, 2001.

[31] M. Somerville, R. Garside, M. Pitt, and K. Stein, "Surveillance of Barrett's oesophagus: is it worthwhile?" *European Journal of Cancer*, vol. 44, no. 4, pp. 588–599, 2008.

[32] S. Gutman and L. G. Kessler, "The US Food and Drug Administration perspective on cancer biomarker development," *Nature Reviews Cancer*, vol. 6, no. 7, pp. 565–571, 2006.

[33] Biomarkers Definitions Working Group, "Biomarkers and surrogate endpoints: preferred definitions and conceptual framework," *Clinical Pharmacology & Therapeutics*, vol. 69, no. 3, pp. 89–95, 2001.

[34] D. J. Brennan, C. Kelly, E. Rexhepaj, P. A. Dervan, M. J. Duffy, and W. M. Gallagher, "Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer," *Cancer Genomics and Proteomics*, vol. 4, no. 3, pp. 121–134, 2007.

[35] M. S. Pepe, R. Etzioni, Z. Feng et al., "Phases of biomarker development for early detection of cancer," *Journal of the National Cancer Institute*, vol. 93, no. 14, pp. 1054–1061, 2001.

[36] L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, B. J. Reid, R. C. Haggitt, C. E. Rubine et al., "Observation variability in the diagnosis of dysplasia in Barrett's esophagus," *Gastroenterology Research and Practice*, vol. 11, Article ID c4372, 2010.

[37] P. Lao-Sirieix, A. Boussiotas, S. R. Kadri et al., "Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic," *Gut*, vol. 58, no. 11, pp. 1451–1459, 2009.

[38] A. M. Rygiew, F. Milano, F. J. Ten Kate et al., "Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens," *Genes Chromosomes and Cancer*, vol. 47, no. 5, pp. 396–404, 2008.

[39] B. J. Reid, D. S. Levine, G. Longton, P. L. Blount, and P. S. Dahberg, "ERBB2 amplifications in esophageal adenocarcinoma," *Annals of Thoracic Surgery*, vol. 78, no. 5, pp. 1790–1800, 2004.

[40] Z. T. Hammoud, L. Dobrolecki, K. A. Kesler et al., "Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern," *Annals of Thoracic Surgery*, vol. 84, no. 2, pp. 384–392, 2007.

[41] L. M. Merlo, N. A. Shah, X. Li et al., "A comprehensive survey of clonal diversity measures in Barrett's esophagus as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens," *Gut*, vol. 58, no. 11, pp. 1451–1459, 2009.

[42] E. G. Barr Fritcher, S. M. Brankley, B. R. Kipp et al., "A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus," *Human Pathology*, vol. 39, no. 8, pp. 1128–1135, 2008.

[43] P. S. Dahberg, B. A. Jacobson, G. Dalal et al., "ERBB2 amplifications in esophageal adenocarcinoma," *Annals of Thoracic Surgery*, vol. 78, no. 5, pp. 1790–1800, 2004.

[44] Z. T. Hammoud, L. Dobrolecki, K. A. Kesler et al., "Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern," *Annals of Thoracic Surgery*, vol. 84, no. 2, pp. 384–392, 2007.

[45] B. J. Reid, D. S. Levine, G. Longton, P. L. Blount, and P. S. Dahberg, "ERBB2 amplifications in esophageal adenocarcinoma," *Annals of Thoracic Surgery*, vol. 78, no. 5, pp. 1790–1800, 2004.

[46] B. J. Reid, D. S. Levine, G. Longton, P. L. Blount, and P. S. Dahberg, "ERBB2 amplifications in esophageal adenocarcinoma," *Annals of Thoracic Surgery*, vol. 78, no. 5, pp. 1790–1800, 2004.

[47] B. J. Reid, D. S. Levine, G. Longton, P. L. Blount, and P. S. Dahberg, "ERBB2 amplifications in esophageal adenocarcinoma," *Annals of Thoracic Surgery*, vol. 78, no. 5, pp. 1790–1800, 2004.

[48] B. J. Reid, D. S. Levine, G. Longton, P. L. Blount, and P. S. Dahberg, "ERBB2 amplifications in esophageal adenocarcinoma," *Annals of Thoracic Surgery*, vol. 78, no. 5, pp. 1790–1800, 2004.

[49] B. J. Reid, D. S. Levine, G. Longton, P. L. Blount, and P. S. Dahberg, "ERBB2 amplifications in esophageal adenocarcinoma," *Annals of Thoracic Surgery*, vol. 78, no. 5, pp. 1790–1800, 2004.

[50] B. J. Reid, D. S. Levine, G. Longton, P. L. Blount, and P. S. Dahberg, "ERBB2 amplifications in esophageal adenocarcinoma," *Annals of Thoracic Surgery*, vol. 78, no. 5, pp. 1790–1800, 2004.
K. Bani-Hani, I. G. Martin, L. J. Hardie et al., “Prospective study of cyclin D1 overexpression in Barrett’s esophagus: association with increased risk of adenocarcinoma,” *Journal of the National Cancer Institute*, vol. 92, no. 16, pp. 1316–1321, 2000.

J. S. Wang, M. Guo, E. A. Montgomery et al., “DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett’s esophagus,” *American Journal of Gastroenterology*, vol. 104, no. 9, pp. 2153–2160, 2009.

Z. Jin, Y. Cheng, W. Gu et al., “A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus,” *Cancer Research*, vol. 69, no. 10, pp. 4112–4115, 2009.

P. S. Dahlberg, L. F. Ferrin, S. M. Nelson, C. D. Hoang, and B. Jacobson, “Gene expression profiles in esophageal adenocarcinoma,” *Annals of Thoracic Surgery*, vol. 77, no. 3, pp. 1008–1015, 2004.

J. Breton, M. C. Gage, A. W. Hay et al., “Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett’s esophagus and esophageal adenocarcinoma,” *Journal of Proteome Research*, vol. 7, no. 5, pp. 1953–1962, 2008.

M. Fang, E. Lew, M. Klein, T. Sebo, Y. Su, and R. Goyal, “DNA abnormalities as marker of risk for progression of Barrett’s esophagus to adenocarcinoma: image cytometric DNA analysis in formal-in-fixed tissues,” *American Journal of Gastroenterology*, vol. 99, no. 10, pp. 1887–1894, 2004.

C. Yu, X. Zhang, Q. Huang, M. Klein, and R. K. Goyal, “High-fidelity DNA histograms in neoplastic progression in Barrett’s esophagus,” *Laboratory Investigation*, vol. 87, no. 5, pp. 466–472, 2007.

N. Vogt, R. Schönegg, J. M. Gschossmann, and J. Borovicka, “Benefit of baseline cytometry for surveillance of patients with Barrett’s esophagus,” *Surgical Endoscopy and Other Interventional Techniques*, vol. 24, no. 5, pp. 1144–1150, 2010.

X. Li, P. C. Galipeau, C. A. Sanchez et al., “Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett’s esophagus neoplastic progression,” *Cancer Prevention Research*, vol. 1, no. 6, pp. 413–423, 2008.

G. A. Prasad, K. K. Wang, K. C. Halling et al., “Utility of biomarkers in prediction of response to ablative therapy in Barrett’s esophagus,” *Gastroenterology*, vol. 135, no. 2, pp. 370–379, 2008.

J. M. Dunn, G. D. MacKenzie, D. Oukrif et al., “Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett’s oesophagus following photodynamic therapy,” *British Journal of Cancer*, vol. 102, no. 11, pp. 1608–1617, 2010.

R. Langer, K. Ott, K. Specht et al., “Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response,” *Clinical Cancer Research*, vol. 14, no. 24, pp. 8279–8287, 2008.

M. Schauer, K. P. Janssen, C. Rinkus et al., “Microarray-based response prediction in esophageal adenocarcinoma,” *Clinical Cancer Research*, vol. 16, no. 1, pp. 330–337, 2010.

X. Wu, J. Gu, T. T. Wu et al., “Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer,” *Journal of Clinical Oncology*, vol. 24, no. 23, pp. 3789–3798, 2006.

P. A. M. Heeren, F. W. H. Kloppenberg, H. Hollema, N. H. Mulder, R. E. Nap, and J. T. M. Plukker, “Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus,” *Anticancer Research*, vol. 24, no. 4, pp. 2579–2583, 2004.

S. Nakashima, S. Natsugoe, M. Matsumoto et al., “Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma,” *Anticancer Research*, vol. 20, no. 3 B, pp. 1933–1937, 2000.

M. K. Kim, K. J. Cho, G. Y. Kwon et al., “ERCCI predicting chemoradiation resistance and poor outcome in oesophageal cancer,” *European Journal of Cancer*, vol. 44, no. 1, pp. 54–60, 2008.

C. J. Peters, J. R. E. Rees, R. H. Hardwick et al., “A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia,” *Gastroenterology*, vol. 139, no. 6, pp. 1995.e15–2004.e15, 2010.

G. A. Prasad, K. K. Wang, K. C. Halling et al., “Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus,” *Cancer*, vol. 113, no. 3, pp. 470–476, 2008.

S. M. Lagarde, P. E. Ver Loren Van Themaat, P. D. Moerland et al., “Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus,” *Annals of Surgical Oncology*, vol. 15, no. 12, pp. 3459–3470, 2008.

E. A. Mathé, G. H. Nguyen, E. D. Bowman et al., “MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival,” *Clinical Cancer Research*, vol. 15, no. 19, pp. 6192–6200, 2009.

G. Pasello, S. Agata, L. Bonaldi et al., “DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients,” *Modern Pathology*, vol. 22, no. 1, pp. 58–65, 2009.

J. G. Izzo, T. T. Wu, X. Wu et al., “Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma,” *Journal of Clinical Oncology*, vol. 25, no. 6, pp. 698–707, 2007.

K. L. Wang, T. T. Wu, S. C. In et al., “Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome,” *Cancer*, vol. 109, no. 4, pp. 658–667, 2007.

R. Langer, B. H. A. Von Rahden, J. Nahrig et al., “Prognostic significance of expression patterns of c-erbB-2, p53, p16 INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study,” *Journal of Clinical Pathology*, vol. 59, no. 6, pp. 631–634, 2006.

D. Falkenback, M. Nilbert, S. Öberg, and J. Johansson, “Prognostic value of cell adhesion in esophagael adenocarcinomas,” *Diseases of the Esophagus*, vol. 21, no. 2, pp. 97–102, 2008.
[90] T. P. Brien, R. D. Odze, C. E. Sheehan, B. J. McKenna, and J. S. Ross, “Her-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma,” Human Pathology, vol. 31, no. 1, pp. 35–39, 2000.

[91] J. S. Ross and B. J. McKenna, “The HER-2/neu oncogene in tumors of the gastrointestinal tract,” Cancer Investigation, vol. 19, no. 5, pp. 554–568, 2001.

[92] T. A. Aloia, D. H. Harpole Jr., C. E. Reed et al., “Tumor marker expression is predictive of survival in patients with esophageal cancer,” Annals of Thoracic Surgery, vol. 72, no. 3, pp. 859–866, 2001.

[93] A. D’Errico, C. Barozzi, M. Fiorentino et al., “Role and new perspectives of transforming growth factor-α (TGF-α) in adenocarcinoma of the gastro-oesophageal junction,” British Journal of Cancer, vol. 82, no. 4, pp. 865–870, 2000.

[94] B. H. A. Von Rahden, H. J. Stein, M. Feith et al., “Overexpression of TGF-β1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis,” Molecular Carcinogenesis, vol. 45, no. 10, pp. 786–794, 2006.

[95] M. Fukuchi, T. Miyazaki, Y. Fukai et al., “Plasma level of APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma,” Journal of the National Cancer Institute, vol. 92, no. 22, pp. 1805–1811, 2000.

[96] A. A. Raouf, D. A. Evoy, E. Carton, E. Mulligan, M. M. Griffin, and J. V. Reynolds, “Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation,” Diseases of the Esophagus, vol. 16, no. 1, pp. 17–23, 2003.

[97] P. Bhandari, A. C. Bateman, R. L. Mehta et al., “Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus,” BMC Cancer, vol. 6, article 134, 2006.

[98] M. France, P. A. Drew, T. Dodd, and D. I. Watson, “Cyclooxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy,” Diseases of the Esophagus, vol. 17, no. 2, pp. 136–140, 2004.

[99] C. J. Buskens, B. P. Van Rees, A. Sivula et al., “Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus,” Gastroenterology, vol. 122, no. 7, pp. 1800–1807, 2002.

[100] J. G. Izzo, U. Malhotra, T. T. Wu et al., “Association of activated transcription factor nuclear factor κB with chemoradiation resistance and poor outcome in esophageal carcinoma,” Journal of Clinical Oncology, vol. 24, no. 5, pp. 748–754, 2006.

[101] R. Gertler, D. Doll, M. Maak, M. Feith, and R. Rosenberg, “Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma,” Cancer, vol. 112, no. 10, pp. 2173–2180, 2008.

[102] R. S. Saad, Y. El-Gohary, E. Memari, Y. L. Liu, and J. F. Silverman, “Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma,” Human Pathology, vol. 36, no. 9, pp. 955–961, 2005.

[103] H. Nekarda, P. Schlegel, M. Schmitt et al., “Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus,” Clinical Cancer Research, vol. 4, no. 7, pp. 1755–1763, 1998.

[104] S. J. Darnton, L. J. Hardie, R. S. Muc, C. P. Wild, and A. G. Casson, “Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis,” International Journal of Cancer, vol. 115, no. 3, pp. 351–358, 2005.

[105] M. V. Brock, M. Gou, Y. Akiyama et al., “Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma,” Clinical Cancer Research, vol. 9, no. 8, pp. 2912–2919, 2003.

[106] S. Baumann, G. Keller, F. Pühringer et al., “The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promoter hypermethylation in esophageal adenocarcinoma,” International Journal of Cancer, vol. 119, no. 2, pp. 264–268, 2006.

[107] C. M. Smith, M. Z. Michael, D. I. Watson et al., “Impact of gastroesophageal reflux on microRNA expression, location and function,” BMC Gastroenterology, vol. 13, no. 1, article 4, 2013.

[108] P. A. Gregory, A. G. Bert, E. L. Paterson et al., “The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIPI,” Nature Cell Biology, vol. 10, no. 5, pp. 593–601, 2008.

[109] A. Russo, G. Bronte, D. Cabibi et al., “The molecular changes driving the carcinogenesis in Barrett's esophagus: which came first, the chicken or the egg?” Critical Reviews in Oncology/Hematology, 2013.

[110] C. A. J. Ong, P. Lao-Sirieix, and R. C. Fitzgerald, “Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis,” World Journal of Gastroenterology, vol. 16, no. 45, pp. 5669–5681, 2010.

[111] D. Fang, K. M. Das, W. Cao et al., “Barrett's esophagus: progression to adenocarcinoma and markers,” Annals of the New York Academy of Sciences, vol. 1232, pp. 210–229, 2011.

[112] Q. Huang and L. J. Hardie, “Biomarkers in Barrett's oesophagus,” Biochemical Society Transactions, vol. 38, no. 2, pp. 343–347, 2010.

[113] J. A. Jankowski and R. D. Odze, “Biomarkers in gastroenterology: between hope and hype comes histopathology,” American Journal of Gastroenterology, vol. 104, no. 5, pp. 1093–1096, 2009.

[114] S. Varghese, P. Lao-Sirieix, and R. C. Fitzgerald, “Identification and clinical implementation of biomarkers for Barrett's esophagus,” Gastroenterology, vol. 142, no. 3, pp. 435–441, 2012.

[115] R. H. Riddell and R. D. Odze, “Definition of Barrett's esophagus: time for a rethink is intestinal metaplasia dead,” American Journal of Gastroenterology, vol. 104, no. 10, pp. 2588–2594, 2009.

[116] L. H. Sobin, M. K. Gospodarowicz, and C. Wittekind, TNM Classification of Malignant Tumours, vol. 7, 7th edition, 2010.

[117] L. H. Moyes and J. J. Going, “Still waiting for predictive biomarkers in Barrett's oesophagus,” Journal of Clinical Pathology, vol. 64, no. 9, pp. 742–750, 2011.

[118] S. Varghese, P. Lao-Sirieix, and R. C. Fitzgerald, “Identification and clinical implementation of biomarkers for Barrett's esophagus,” Gastroenterology, vol. 142, no. 3, pp. 435–441, 2012.

[119] A. Poehlmann, D. Kusterer, P. Malfertheiner et al., “Inflammation and Barrett's carcinogenesis,” Pathology, Research and Practice, vol. 208, no. 5, pp. 269–280, 2012.

[120] T. Kiesslich, M. Pichler, and D. Neureiter, “Epidigenetic control of epithelial-mesenchymal-transition in human cancer (Review),” Molecular and Clinical Oncology, vol. 1, pp. 3–11, 2013.

[121] P. Jethwa, M. Naqvi, R. G. Hardy et al., “Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma,” World Journal of Gastroenterology, vol. 14, no. 7, pp. 1044–1052, 2008.
[123] E. L. Bird-Lieberman, J. M. Dunn, H. G. Coleman et al., “Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus,” *Gastroenterology*, vol. 143, no. 4, pp. 927–935, 2012.

[124] E. M. El Omar and J. Jankowski, “Genetics of Barrett’s: the bigger, the better,” *American Journal of Gastroenterology*, vol. 107, no. 9, pp. 1342–1345, 2012.

[125] A. M. Kaz, C. J. Wong, Y. Luo et al., “DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses,” *Epigenetics*, vol. 6, no. 12, pp. 1403–1412, 2011.

[126] M. A. Ko, G. Zehong, C. Virtanen et al., “MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy,” *Annals of Thoracic Surgery*, vol. 94, no. 4, pp. 1094–1102, 2012.